SCHEMBL6754286

SCHEMBL6754286

Nc1cc(Cl)cc(NC(=O)/C=C/c2c[nH]c3ccccc23)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.49
▸ MEN1 O00255 7/20 0.48
▸ KMT2A Q03164 7/20 0.48
▸ MAPT P10636 5/20 0.48
▸ NPC1 O15118 5/20 0.48
▸ RAB9A P51151 5/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ HPGD P15428 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ HDAC1 Q13547 2/20 0.48
▸ IMPDH2 P12268 1/20 0.47
▸ BACE1 P56817 2/20 0.46
▸ JAK3 P52333 1/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6754291 1.00 EGFR (0.49) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL31447950 0.85 MAOB (0.60) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL6756819 0.83 NPC1 (0.53) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL6756739 0.80 RAB9A (0.66) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL6756742 0.80 RAB9A (0.66) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL6756745 0.80 RAB9A (0.66) EGFRMEN1KMT2AMAPTNPC1
SCHEMBL18929474 0.79 MEN1 (0.55) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL29678247 0.76 PARP1 (0.58) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL2085438 0.76 PARP1 (0.58) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL2085437 0.76 PARP1 (0.58) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 EGFR 1431/4885MEN1 970/4885KMT2A 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback